Tutores

Reposicionamiento terapeútico de farmacos contra el cáncer.
Evaluación inmunológica de la inhibicion metabólica en diferentes líneas de cáncer con base en el tratamiento de la polifarmacia.

1. Scholnik-Cabrera A, Chávez-Blanco AD., Domínguez-Gómez, Juarez M. Lai D., Hua S., Tovar AR., Díaz-Chávez J.Dueñas-González A. The combination of orlistat, lonidamine and 6 diazo 5 oxo L norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells. Oncol Lett. 2020, 20(3):3053-30360. Impact Factor 2022: 3.11
2. Soria-Castro R, Chávez-Blanco AD, García-Pérez BE, Wong-Baeza I, Flores-Mejía R, Flores-Borja F, Estrada-Parra S, Estrada-García I, Serafín-López J, Chacón-Salinas R. Valproic acid inhibits interferon-γ production by NK cells and increases susceptibility to Listeria monocytogenes infection. Sci Rep. 2020;10(1):17802. Impact factor 2021: 6.011 doi: 10.1038/s41598-020-74836-w. PMID: 33082490
3. Muñoz AM, Fragoso-Vázquez MJ, Martel BP, Chávez-Blanco A, Dueñas-González A, R García-Sánchez J, Bello M, Romero-Castro A, Correa-Basurto. Targeting Breast Cancer Cells with G4 PAMAM Dendrimers and Valproic Acid Derivative Complexes. Anticancer Agents Med Chem. 2020; 20(15):1857-1872. Impact factor 2023: 2.8 doi: 10.2174/1871520620666200423073812.PMID: 32324521
4. Taja-Chayeb L., Cetina L, Cruz-Velazquez J, Perez-Montiel D, Moreno-Soriano N., Jimenez-Lima R, Rivera-Marquez R, Trejo-Becerril C, Pérez-Cárdenas E, Chávez-Blanco AD, Domínguez-Gómez G, Dueñas-González A. Investigation of HER-2 status, treatment response and survival analysis in cervical cancer patients. European Journal of Gynaecological Oncology, 2020, Vol. 41(6): 1031-1038. Impact factor 2023: 0.4 DOI: 10.31083/j.ejgo.2020.06.2115
5. Rodríguez-López GM, Soria-Castro R, Campillo-Navarro M, Pérez-Tapia SM, Flores-Borja F, Wong-Baeza I, Muñoz-Cruz S, López-Santiago R, Estrada-Parra S, Estrada-García I, Chávez-Blanco AD, Chacón-Salinas R. The histone deacetylase inhibitor valproic acid attenuates phospholipase Cγ2 and IgE-mediated mast cell activation. J Leukoc Biol. 2020 Sep;108(3):859-866. Impact factor 2023: 5.5 doi: 10.1002/JLB.3AB0320-547R. PMID: 32480423.
6. Juarez M, Schcolnik-Cabrera A, Domínguez-Gómez G, Chávez-Blanco A, Díaz-Chávez J, Dueñas-González A. Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. Cancer Chemother Pharmacol. 2020 Jun; 85(6):1153-1163. Impact factor 2021 : 6.737 doi: 10.1007/s00280-020-04041-z.PMID: 32474842
7. Castillo-Juárez P, Sanchez SC, Chávez-Blanco AD, Mendoza-Figueroa H, Correa-Basurto. Apoptotic Effects of N-(2-hydroxyphenyl)-2-propylpentanamide on U87-MG and U-2 OS Cells and Antiangiogenic Properties. Anticancer Agents Med Chem. 2021; 21(11): Impact factor 2023: 2.8 doi: 10.2174/1871520620666200728125356. PMID: 32723256.
8. Schcolnik-Cabrera A, Chávez-Blanco A, Domínguez-Gómez G, Juarez M, Vargas-Castillo A, Ponce-Toledo RI, Lai D, Hua S, Tovar AR, Torres N, Pérez-Montiel D, Díaz-Chávez J, Dueñas-González A. Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy. Scientific Reports. 2021, 11(1): 1-14. Impact factor 2022: 4.6 doi: 10.1038/s41598-021-84538-6.
9. Soria-Castro R, Alfaro-Doblado ÁR, Rodríguez-López G, Campillo-Navarro M, Meneses-Preza YG, Galán-Salinas A, Alvarez-Jimenez V, Yam-Puc JC, Munguía-Fuentes R, Domínguez-Flores A, Estrada-Parra S, Pérez-Tapia SM, Chávez-Blanco AD, Chacón-Salinas R. TLR2 Regulates Mast Cell IL-6 and IL-13 Production During Listeria monocytogenes Infection. Frontiers in Immunology. 2021 Jun 14;12:650779. doi: 10.3389/fimmu.2021.650779. eCollection 2021. Impact factor 2022: 7.3
10. Soria-Castro R, Meneses-Preza YG, Rodríguez-López GM, Romero-Ramírez S, Sosa-Hernández VA, Cervantes-Díaz R, Pérez-Fragoso A, Torres-Ruíz JJ, Gómez-Martín D, Campillo-Navarro M, Álvarez-Jiménez VD, Pérez-Tapia SM, Chávez-Blanco AD, Estrada-Parra S, Maravillas-Montero JL, Chacón-Salinas R. Severe COVID-19 is marked by dysregulated serum levels of carboxypeptidase A3 and serotonin. J Leukoc Biol. 2021 Sep;110(3):425-431. doi: 10.1002/JLB.4HI0221-087R. Impact factor 2023: 5.5.
11. Soria‑Castro R., Meneses‑Preza YG, G. Rodríguez‑López GM, Ibarra‑Sánchez A, Claudia González‑Espinosa3, Sonia M. Pérez‑Tapia1,4, Fabián Flores‑Borja5, Sergio Estrada‑Parra1,. Chávez‑Blanco AD, Chacón‑Salinas R., Valproic acid restricts mast cell activation by Listeria monocytogenes. Sci Rep. 2022 Sep 20;12(1):15685. doi: 10.1038/s41598-022-20054-5. Impact factor 2022: 4.6
12. Romo-Perez A, Domínguez-Gómez G, Chávez-Blanco A, Taja-Chayeb L, González- Fierro A, Díaz-Romero C, López-Basave HN, Dueñas-González A. Progress in Metabolic Studies of Gastric Cancer and Therapeutic Implications. Curr. Cancer Drug Targets. 2022 Apr 13. doi: 10.2174/1568009622666220413083534. Impact factor 2019: 2.912.
13. Romo-Perez A, Domínguez-Gómez G, Chávez-Blanco A, Taja-Chayeb L, González-Fierro A, García-Martínez E, Correa-Basurto J, Dueñas-González A. BAPST. A Combo of Common Use Drugs as Metabolic Therapy for Cancer: A Theoretical Proposal. Curr Mol Pharmacol.2022;15(6):815-831. doi: 10.2174/1874467214666211006123728. Impact factor 2021: 2.7
14. Taja-Chayeb L, Vidal-Millán S, Trejo-Becerril C, Pérez-Cárdenas E, Chávez-Blanco A, Domínguez-Gómez G, González-Fierro A, Romo-Pérez A, Dueñas-González A. Hereditary diffuse gastric cancer (HDGC). An overview. Clin Res Hepatol Gastroenterol. 2022 Apr;46(4):101820. doi: 10.1016/j.clinre.2021.101820. Impact factor 2021: 3.189
15. Gonzalez-Fierro A, Romo-Pérez A, Chávez-Blanco A, Dominguez- Gomez G. and Dueñas-Gonzalez A. Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a Lower Price. Clini Drug Investig. 2023. Apr; 43 (4):227-239. Impact factor 2022: 3.2. https://doi.org/10.1007/s40261-023-01251-0.
16. Dominguez-Flores A., Rodríguez López GM., Soria-Castro R., Ruben López-Santiago R., Rodríguez-Cortés O., Pérez-Tapia SM., Chávez- Blanco AD., Estrada-Parra S., Flores-Mejía R., Chacón-Salinas R. Brucella abortus induces mast cell activation through TLR-2 and TLR-4. Microbial Pathogenesis. 2023. 176:106005. pp.1.6 doi: 10.1016/j.micpath.2023.106005. Impact factor 2023: 3.8
17. Romo-Perez A, Guadalupe Domínguez-Gómez G., Chávez-Blanco A., González-Fierro A., Correa-Basurto J., Dueñas-González A. PaSTe. Blockade of the Lipid Phenotype of Prostate Cancer as Metabolic Therapy: A Theoretical Proposal. Curr Med Chem. 2023 August; 31 (22): 3265-3285. Impact factor 2022: 4.1 doi: 10.1007/s40261-023-01251-0. Epub 2023
18. Robles-Bañuelos B, Romo-Perez A, Dominguez-Gomez G, Chavez-Blanco A, Gonzalez-Fierro A, Duenas-Gonzalez A. Selection of clinically relevant drug concentrations for in vitro studies of candidates drugs for cancer repurposing: a proposal. Clin Transl. Oncol. 2023. Dec 8. doi: 10.1007/s12094-023-03352-w. Impact factor 2022: 3.4
19. De La Cruz‑Sigüenza DA., Reyes‑Grajeda JP., Velasco‑Vel.zquez MA., Trejo‑Becerril C., Pérez‑Cardenas E., Chávez‑Blanco A., Taja‑Chayeb L., Domínguez‑Gómez G., Ramos‑Godinez MP. González‑Fierro A., Dueñas‑González. The non‑vesicle cell‑free DNA (cfDNA) induces cell transformation associated with horizontal DNA transfer. Molecular Biology Reports. 2024. 51:174 Impact factor 2022: 2.8 doi.org/10.1007/s11033-023-09016-w
20. Meneses-Preza YG, Martínez-Martínez R, Meixueiro-Calderón C, Hernández UM, Retana EA, Ponce-Regalado MD, Gamboa-Domínguez A, León-Contreras JC, Muñoz-Cruz S, Hernández-Pando R, Pérez-Tapia SM, Chávez-Blanco AD, Becerril-Villanueva E, Chacón-Salinas R. Mast Cell Carboxypeptidase A3 Is Associated with Pulmonary Fibrosis Secondary to COVID-19. Int J Mol Sci. 2024 Nov 14;25(22):12258. doi: 10.3390/ijms252212258. Impact factor 2023: 4.9.
21. Prestegui Martel B, Chávez-Blanco AD, Domínguez-Gómez G, Dueñas González A, Gaona-Aguas P, Flores-Mejía R, Somilleda-Ventura SA, Rodríguez-Cortes O, Morales-Bárcena R, Martínez Muñoz A, Mejia Barradas CM, Mendieta Wejebe JE, Correa Basurto J N-(2-Hydroxyphenyl)-2-Propylpentanamide (HO-AAVPA) Induces Apoptosis and Cell Cycle Arrest in Breast Cancer Cells, Decreasing GPER Expression. Molecules. 2024 Jul 26;29(15):3509. doi: 10.3390/molecules29153509. Impact factor 2023: 4.2
22. Salamanca-Ortiz H, Domínguez-Gomez G, Chávez-Blanco A, Ortega-Bernal D, Díaz-Chávez J, González-Fierro A, Candelaria-Hernández M, Dueñas-González A.
The inhibitory and transcriptional effects of the epigenetic repurposed drugs hydralazine and valproate in lymphoma cells. Am J Cancer Res. 2024 Jun 15;14(6):3068-3082. doi: 10.62347/IDKG8587. eCollection 2024. Impact factor 2023: 3.6
23. González-Fierro A, Domínguez-Gomez G, , Chávez-Blanco A, Dueñas-González A.
Pharmacokinetics and pharmacodynamics of angiogenesis inhibitors used to treat cervical cancer: current and future. Expert Opin Drug Metab Toxicol. 2025 Jan-Feb;21(2):133-141. doi: 10.1080/17425255.2024.2401586. Epub 2024 Sep 9. Impact factor
24. Villareal-Rivota B, Meneses-Preza YG, Campillo-Navarro M, Ruiz-Sánchez BP, Soria-Castro R, Barrios-Payán J, Mata-Espinosa D, Donis-Maturano L, Pérez-Tapia SM, Chávez-Blanco AD, Estrada-Parra S, Hernández-Pando R, Chacón-Salinas R. Impaired control of Mycobacterium tuberculosis infection in mast cell-deficient KitW-sh/W-sh mice. Tuberculosis (Edinb). 2025 Jan; 150:102587. doi: 10.1016/j.tube.2024.102587. Impact factor 2023: 2.8.
25. Meneses-Preza YG, Soria-Castro R, Alfaro-Doblado ÁR, Hernández-Solis A, Álvarez-Maldonado P, Gómez-Martín D, Torres-Ruiz J, Muñoz-Valle JF, Muñoz-Ríos G, Hernández-Ramírez CO, Güemes-González AM, Wong-Baeza I, Maravillas-Montero JL, Pérez-Tapia SM, Chávez-Blanco AD, Estrada-Parra S, Chacón-Salinas R. Mast cell activation signature as a potential biomarker in COVID-19. Immunol Lett. 2025 Apr 16; 275:107026. doi: 10.1016/j.imlet.2025.107026. Impact factor 2023: 3.3